Is TB-500 Legal in 2026?

Key Takeaways

• Controlled-substance status: TB-500 is not expressly listed by name in the U.S. federal controlled-substance schedules.

• FDA approval: TB-500 has no FDA-approved human drug product or approved therapeutic indication.

• Compounding: A July 2026 advisory committee recommended adding TB-500-related substances to the Section 503A Bulks List. The recommendation was non-binding and did not itself authorize routine compounding.

• Research-use labeling: A “for research use only” label does not automatically make every sale, distribution, or use lawful.

• Sports regulations: TB-500 is prohibited at all times under the 2026 World Anti-Doping Agency (WADA) Prohibited List.

• International laws: Rules governing medicines, imports, and research materials vary by country.

Is TB-500 Legal in the United States?

The answer depends on what “legal” means in a particular situation. Controlled-substance scheduling, FDA drug regulation, pharmacy compounding, and anti-doping rules are separate legal frameworks.

TB-500 is a synthetic peptide fragment associated with thymosin beta-4. It has attracted research interest in areas involving tissue repair, but research interest does not establish that a substance is safe or effective as a treatment for people.

TB-500 is not expressly listed by name in the federal Controlled Substances Act schedules. However, this does not establish that every product, transaction, or intended use is lawful. Other federal and state requirements may apply, depending on the circumstances.

The FDA separately regulates drugs and products marketed for human treatment. A substance can fall outside the controlled-substance schedules while still being subject to restrictions involving unapproved drugs, marketing claims, manufacturing, distribution, and compounding.

The key distinction: Not being expressly listed as a controlled substance is not the same as being FDA-approved or authorized for human treatment.

Is TB-500 FDA-Approved?

No. As of October 2026, TB-500 has no FDA-approved human drug product or approved medical indication.

FDA approval involves evaluating evidence about a drug's safety and effectiveness for a specific intended use. The appearance of a substance in scientific literature, a research database, or an advisory committee meeting does not mean it has completed that process.

In 2026, the FDA reviewed TB-500-related substances in connection with possible inclusion on a list of bulk drug substances that may be used in certain pharmacy-compounding circumstances. The review highlighted gaps in the available evidence, including limited human-use information and concerns about adequately characterizing the substances.

Consequently, claims that TB-500 is a proven treatment for injuries, tendon problems, muscle recovery, or other medical conditions should not be presented as established clinical benefits.

What Changed in 2026? FDA Compounding Review

A significant regulatory development in 2026 was the review of TB-500-related bulk drug substances for possible inclusion on the FDA's Section 503A Bulks List.

The earlier regulatory position

TB-500's removal from Category 2 following withdrawal of a nomination did not mean it had been approved or added to the list of bulk drug substances eligible for compounding under Section 503A.

A change in a nomination's status is not equivalent to FDA approval, and it does not independently establish that a substance can be routinely compounded for human treatment.

The July 2026 advisory committee vote

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee considered TB-500-related substances, including free-base and acetate forms, for possible inclusion on the Section 503A Bulks List.

The committee recommended inclusion. However, advisory committee recommendations are non-binding. The FDA retains responsibility for making the relevant regulatory decisions.

A committee vote does not itself add a substance to the list, approve a drug, or establish an approved medical treatment.

The FDA's briefing materials also raised concerns about the available evidence, including inadequate substance characterization and insufficient human-use information to assess clinical safety and effectiveness.

What this means: The July 2026 recommendation was a regulatory development, not FDA approval. The current official list and any subsequent final FDA action should be checked before making a definitive statement about the latest compounding status.

What is Section 503A?

Section 503A establishes conditions under which state-licensed pharmacists and physicians may compound certain drugs for individual patients. It is not a general exemption that makes every research chemical eligible for pharmacy compounding.

Compounded drugs are not FDA-approved. The FDA does not evaluate their safety, effectiveness, and quality before marketing in the same way it evaluates approved drugs.

Does “For Research Use Only” Make TB-500 Legal for Any Use?

No. A label is not a blanket legal exemption.

The phrase “for research use only” describes a stated purpose, but it does not override applicable laws. Regulators may consider a product's intended use, marketing, claims, and actual circumstances when determining which legal requirements apply.

It is important to distinguish among three contexts:

• Laboratory research: Research activities must comply with applicable legal, institutional, and safety requirements.

• Human treatment: Use intended to diagnose, prevent, mitigate, treat, or cure a disease or condition raises separate drug-regulatory questions.

• Commercial marketing: Claims that a product treats injuries or improves health may trigger drug requirements that do not disappear simply because a label says “research use only.”

A product's label is therefore not proof that it is suitable for human use, lawfully marketed for treatment, or exempt from all regulatory requirements.

Is TB-500 a Controlled Substance?

TB-500 is not expressly named in the federal Controlled Substances Act schedules. However, the absence of a substance's name from a schedule does not settle every possible legal question involving a product or related substance.

This is a narrower conclusion than saying that buying, selling, possessing, importing, or administering every TB-500 product is lawful in all circumstances.

The legal status of a particular transaction may depend on the product, intended use, applicable federal and state law, and other regulatory requirements.

Anyone who needs a decision about a specific situation should consult a qualified legal professional or the relevant regulator.

Is TB-500 Banned by WADA in 2026?

Yes. TB-500 is named in the 2026 WADA Prohibited List under category S2.3, which covers growth factors and growth-factor modulators.

The list identifies thymosin beta-4 and its derivatives, including TB-500. The S2 category is prohibited both in and out of competition.

This is a sports-regulation issue, not the same as criminal-law scheduling.

For athletes subject to an anti-doping code that adopts the WADA list, a substance can result in an anti-doping rule violation even if it is not a federally scheduled controlled substance. Athletes should consult their governing anti-doping organization for guidance about their obligations.

Are State Laws Different?

Federal law does not answer every state-law question.

States may regulate medical practice, pharmacy activity, drug distribution, and other conduct through their own laws and professional licensing systems. The fact that TB-500 is not expressly listed in the federal controlled-substance schedules does not establish that every state-level question has the same answer.

Claims that no state has enacted a relevant restriction should be supported by a current, comprehensive review of state statutes and regulations. Without that review, it is more accurate to say that state-specific requirements may apply and should be checked where relevant.

Is TB-500 Legal Outside the United States?

There is no single international rule that determines TB-500's legal status worldwide.

Countries may regulate a substance differently depending on whether it is treated as a medicine, an investigational product, a research chemical, or a substance subject to import controls. Rules can also differ between possession, supply, importation, and administration to people.

A country-specific legal conclusion requires current information from the relevant medicines regulator, customs authority, and applicable legislation. The absence of TB-500 from a country's controlled-drug list alone does not establish that its import or human use is lawful.

For this reason, broad claims that TB-500 is “legal in most Western countries” should not be made without current, jurisdiction-specific evidence.

What Safety Concerns Has the FDA Identified?

The FDA has identified potential safety concerns involving TB-500-related substances, including:

• Potential immunogenicity associated with certain routes of administration.

• Peptide aggregation.

• Peptide-related impurities.

• Limited human exposure information needed to assess potential harm.

These concerns do not establish that every possible exposure will cause harm. They do mean that safety cannot be assumed from online claims, product labeling, or anecdotal reports.

Laboratory research and limited preliminary evidence are not substitutes for adequate clinical studies. In particular, the lack of robust human safety and effectiveness data means TB-500 should not be described as a proven treatment or as risk-free.

TB-500 Legal Status: Quick Reference

Frequently Asked Questions

Is TB-500 legal in the U.S. in 2026?

There is no single yes-or-no answer that covers every transaction and intended use. TB-500 is not expressly listed by name in the federal controlled-substance schedules, but it is not FDA-approved for human treatment. Drug marketing, compounding, distribution, importation, and use may raise separate legal issues.

Did the July 2026 FDA vote make TB-500 legal to compound?

No. The advisory committee recommended inclusion of TB-500-related substances on the Section 503A Bulks List, but the vote was not binding on the FDA. A recommendation is not the same as a final FDA action or drug approval.

Is TB-500 an FDA-approved medicine?

No. As of October 2026, TB-500 has no FDA-approved human drug product or approved therapeutic indication.

Does a research-use-only label make TB-500 legal for human use?

No. The label does not override applicable drug laws or establish that a product is safe, effective, or approved for human use.

Is TB-500 prohibited in tested sports?

Yes. The 2026 WADA Prohibited List names TB-500 under S2.3, within a category prohibited both in and out of competition.

Is TB-500 legal in every U.S. state?

That conclusion should not be made without reviewing current state laws and relevant professional regulations. Federal controlled-substance status is only one part of the legal analysis.

Is TB-500 legal internationally?

Rules differ across jurisdictions. Medicine regulation, customs requirements, import restrictions, and research rules must be assessed using current information for the particular country.

Conclusion

TB-500's legal status in 2026 cannot be reduced to the statement that it is “legal to buy.” It is not expressly listed by name in the federal controlled-substance schedules, but it is not FDA-approved for human treatment. Its regulatory status also involves drug-marketing rules, compounding requirements, state law, import rules, and sports regulations.

The July 2026 advisory committee rec

expressly listed in the federal controlled-substance schedules does not establish that every state-level question has the same answer.

Claims that no state has enacted a relevant restriction should be supported by a current, comprehensive review of state statutes and regulations. Without that review, it is more accurate to say that state-specific requirements may apply and should be checked where relevant.

Is TB-500 Legal Outside the United States?

There is no single international rule that determines TB-500's legal status worldwide.

Countries may regulate a substance differently depending on whether it is treated as a medicine, an investigational product, a research chemical, or a substance subject to import controls. Rules can also differ between possession, supply, importation, and administration to people.

A country-by-country legal conclusion requires current primary sources from the relevant medicines regulator, customs authority, and applicable legislation. The absence of TB-500 from a country's controlled-drug list alone does not establish that its import or human use is lawful.

For that reason, broad claims that TB-500 is “legal in most Western countries” should be avoided unless they are supported by current, jurisdiction-specific legal research.

What Safety Concerns Has the FDA Identified?

The FDA's published safety information states that compounded drugs containing TB-500 may pose risks related to immunogenicity for certain routes of administration, peptide aggregation, and peptide-related impurities. The agency also notes that it lacks important human exposure information needed to understand potential harm.

These concerns do not establish that every possible exposure will cause harm. They do mean that safety cannot be assumed from online claims, product labeling, or anecdotal reports.

Laboratory research and limited preliminary evidence are not substitutes for adequate clinical studies. In particular, the absence of robust human safety and effectiveness data means that TB-500 should not be described as a proven treatment or as risk-free.

TB-500 Legal Status: Quick Reference

Frequently Asked Questions

Is TB-500 legal in the U.S. in 2026?

There is no single yes-or-no answer covering every transaction and intended use. TB-500 is not expressly listed by name in the federal controlled-substance schedules, but it is not FDA-approved for human treatment. Drug marketing, compounding, distribution, importation, and use may raise separate legal issues.

Did the July 2026 FDA vote make TB-500 legal to compound?

No. The advisory committee recommended inclusion of TB-500-related substances on the 503A Bulks List, but the vote was not binding on the FDA. A recommendation is not the same as a final FDA action or drug approval.

Is TB-500 an FDA-approved medicine?

No. As of October 2026, TB-500 has no FDA-approved human drug product or approved therapeutic indication.

Does a research-use-only label make TB-500 legal for human use?

No. The label does not override applicable drug laws or establish that a product is safe, effective, or approved for human use.

Is TB-500 prohibited in tested sports?

Yes. The 2026 WADA Prohibited List names TB-500 under S2.3, within a category prohibited both in and out of competition.

Is TB-500 legal in every U.S. state?

That conclusion should not be made without reviewing current state laws and relevant professional regulations. Federal controlled-substance status is only one part of the legal analysis.

Is TB-500 legal internationally?

Rules differ across jurisdictions. Medicine regulation, customs requirements, import restrictions, and research rules must be assessed using current official sources for the particular country.

Conclusion

TB-500's legal status in 2026 cannot be reduced to the statement that it is “legal to buy.” It is not expressly listed by name in the federal controlled-substance schedules, but it is not FDA-approved for human treatment. Its regulatory status also involves drug-marketing rules, compounding requirements, state law, import rules, and sports regulations.

The July 2026 advisory committee recommendation was an important development, but it did not itself approve TB-500 or automatically authorize routine compounding. The 2026 WADA Prohibited List separately prohibits TB-500 in sport at all times.

The most accurate takeaway is that controlled-substance scheduling, FDA approval, compounding eligibility, and anti-doping status are distinct questions. Each must be evaluated on its own terms, using current official sources.

Editorial note: This article is for general educational purposes and is not legal or medical advice. Regulatory status can change. Check the relevant official agency or consult a qualified professional for advice about a specific situation.